Tag Archives: ARWR
Thursday’s Highlights at Noon: Arrowhead Research (ARWR), Kandi Technologies (KNDI), Sandstorm Gold (SAND), First Majestic Silver (AG)
So far Thursday, October 17, NASDAQ is down -1.12% and the S&P is down -0.36%. Here are this morning’s most active stocks: Arrowhead Research (ARWR – Research Report), Kandi Technologies (KNDI – Research Report), Sandstorm Gold (SAND – Research Report)
Monday’s Midday Movers: Agios Pharma (AGIO), Arrowhead Research (ARWR), Novavax (NVAX), Heron Therapeutics (HRTX), Pacira Pharmaceuticals (PCRX)
So far Monday, September 30, NASDAQ is up 2.04% and the S&P is up 1.39%. Let’s take a look at this morning’s most active stocks and their recent analyst insights; Agios Pharma (AGIO – Research Report), Arrowhead Research (ARWR –
Monday’s Midday Stock Update: ACADIA Pharmaceuticals Inc (ACAD), Exact Sciences (EXAS), Arrowhead Research (ARWR), Rite Aid Corp (RAD), Veeva Systems (VEEV)
So far Monday, September 9, NASDAQ is down -1.54% and the S&P is down -1.26%. Let’s take a look at this morning’s most active stocks and their recent analyst insights; ACADIA Pharmaceuticals Inc (ACAD – Research Report), Exact Sciences (EXAS
The CEO of Arrowhead Research is Exercising Options
Yesterday it was reported that the CEO of Arrowhead Research (ARWR – Research Report), Christopher Richard Anzalone, exercised options to buy 49,448 ARWR shares at $2.12 a share, for a total transaction value of $105.1K. Following Christopher Richard Anzalone’s last
The General Counsel of Arrowhead Research (NASDAQ: ARWR) is Selling Shares
Yesterday, the General Counsel of Arrowhead Research (ARWR – Research Report), Patrick O. O’Brien, sold shares of ARWR for $746.4K. In addition to Patrick O. O’Brien, one other ARWR executive reported Sell trades in the last month. See today’s analyst
Arrowhead Research (ARWR) Received its Third Buy in a Row
After Piper Jaffray and Cantor Fitzgerald gave Arrowhead Research (NASDAQ: ARWR) a Buy rating last month, the company received another Buy, this time from B.Riley FBR. Analyst Mayank Mamtani maintained a Buy rating on Arrowhead Research today and set a
